Findings

What do systematic reviews say?

232 questions · 236 findings · 25 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 35 · 14.8%GRADE not reported 3 · 1.3%Very low 49 · 20.8%Low 69 · 29.2%Moderate 69 · 29.2%High 11 · 4.7%

Intervention not reported

Grade 3 to 4 diarrhoea · people with metastatic colorectal cancer ‐ extended RAS WT

The review found no eligible studies for this question.

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Grade 3 to 4 rash · people with metastatic colorectal cancer ‐ extended RAS WT

The review found no eligible studies for this question.

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Grade 3 to 4 neutropenia · people with metastatic colorectal cancer ‐ extended RAS WT

The review found no eligible studies for this question.

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Quality of life · people with metastatic colorectal cancer ‐ extended RAS WT

The review found no eligible studies for this question.

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Progression‐free survival · people with metastatic colorectal cancer ‐ extended RAS MT

The intervention showed no clear difference in progression‐free survival (moderate certainty).

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
HR 1.13 [0.93, 1.36]
6 studies · 2023 participants
Moderate

Intervention not reported

Overall survival · people with metastatic colorectal cancer ‐ extended RAS MT

The intervention showed no clear difference in overall survival (moderate certainty).

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
HR 1.09 [0.93, 1.28]
4 studies · 1768 participants
Moderate

Intervention not reported

Tumour response rate · people with metastatic colorectal cancer ‐ extended RAS MT

The intervention showed no clear difference in tumour response rate (moderate certainty).

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
OR 0.76 [0.55, 1.05]
3 studies · 840 participants
Moderate

Intervention not reported

Overall grade 3 to 4 toxicity · people with metastatic colorectal cancer ‐ extended RAS MT

The review found no eligible studies for this question.

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Grade 3 to 4 diarrhoea · people with metastatic colorectal cancer ‐ extended RAS MT

The review found no eligible studies for this question.

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Grade 3 to 4 rash · people with metastatic colorectal cancer ‐ extended RAS MT

The review found no eligible studies for this question.

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Grade 3 to 4 neutropenia · people with metastatic colorectal cancer ‐ extended RAS MT

The review found no eligible studies for this question.

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Quality of life · people with metastatic colorectal cancer ‐ extended RAS MT

The review found no eligible studies for this question.

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Chemotherapy plus involved‐field radiation vs same chemotherapy plus extended‐field radiation

Secondary malignant neoplasms · Patients with untreated Hodgkin lymphoma (early stages)

Chemotherapy plus involved‐field radiation showed no clear difference in secondary malignant neoplasms compared with same chemotherapy plus extended‐field radiation (low certainty).

1 finding from 1 review

Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant… 2017 · Cochrane Headline outcomes only
OR 0.86 [0.64, 1.16]
4 studies · 2397 participants
Low

Chemotherapy plus involved‐field radiation vs same chemotherapy plus extended‐field radiation

Death · Patients with untreated Hodgkin lymphoma (early stages)

Chemotherapy plus involved‐field radiation showed no clear difference in death compared with same chemotherapy plus extended‐field radiation (high certainty).

1 finding from 1 review

Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant… 2017 · Cochrane Headline outcomes only
HR 0.89 [0.7, 1.12]
4 studies · 2397 participants
High

Chemotherapy plus involved‐field radiation vs same chemotherapy plus extended‐field radiation

Progression/relapse · Patients with untreated Hodgkin lymphoma (early stages)

Chemotherapy plus involved‐field radiation showed no clear difference in progression/relapse compared with same chemotherapy plus extended‐field radiation (high certainty).

1 finding from 1 review

Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant… 2017 · Cochrane Headline outcomes only
HR 0.99 [0.81, 1.21]
4 studies · 2397 participants
High

Orthodontic treatment with appliances inducing stable, permanent orthodontic tooth movement (splints worn 8 to 12 weeks and surgical interventions excluded) vs Control: no treatment, placebo, or reassurance

Development of TMD (onset/incidence of signs and symptoms) · People without TMD at baseline undergoing orthodontic treatment (TMD clinically absent at baseline); no age restriction provided follow-up…

The review found no eligible studies for this question.

1 finding from 1 review

Orthodontics for treating temporomandibular joint (TMJ) disorders 2010 · Cochrane All outcomes
Follow-up period extended into adulthood
no estimate extracted
0 studies
No studies found

Heparin vs placebo

Symptomatic VTE · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Heparin showed no clear difference in symptomatic VTE (DVT and PE) Treatment duration 28 ‐ 42 days compared with placebo (high certainty).

1 finding from 1 review

Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or… 2016 · Cochrane Headline outcomes only
OR 0.59 [0.35, 1.01]
5 studies · 2329 participants
High

Vitamin K antagonists vs placebo

Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Vitamin K antagonists showed no clear difference in bleeding ‐ major Treatment duration 28 ‐ 42 days compared with placebo (low certainty).

1 finding from 1 review

Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or… 2016 · Cochrane Headline outcomes only
OR 2.89 [0.12, 71.31]
1 study · 360 participants
Low

Vitamin K antagonists vs placebo

Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or… 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Vitamin K antagonists vs placebo

Minor bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or… 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found